Commentaries

Defending the cornea with antibacterial fragments of keratin

Michael Zasloff
Georgetown Transplant Institute, Georgetown University School of Medicine, Washington, DC, USA.

In addition to its role in refraction, the cornea forms a barrier between the eye and environmental and infectious insults. Corneal infections are surprisingly rare, suggesting that multiple aspects of the immune system are at play in mediating protection. In this issue of the JCI, Tam et al. describe the unexpected role of a structural protein, cytoketatin 6A, in this process.

The usual healthy appearance of the cornea and conjunctivae of the human eye should puzzle you. Why is it that this surface looks so healthy, most of the time? How is it that despite the almost certain diversity of microbes that come in contact with it, we so rarely see infection, or its associated inflammation, evidence of the body’s mechanisms that are called forth to fight off microorganisms? Lysozyme in tears can defend the eye, but organisms that inhabit the upper airway, such as Staphyloccocus aureus are resistant to this enzyme (1), and other antimicrobial systems must be at work, because in the various dry-eye syndromes, the reduced tear production is not associated with frequent bacterial infections. More perplexing is the fact that a corneal transplant will not necessarily develop infections at the incision or around the suture tracks, and antibiotics are not necessarily required postoperatively (2). Thus, even the wounded cornea seems to handle microbes in some mysterious — and remarkably effective — fashion.

Layers of Protection

The cornea is a wonderful, close-up example of a site protected almost completely by the chemical and physical defenses of our innate immune system. Tears contain high concentrations (about 1 to 2 mg/ml) of each of three antimicrobial proteins: lysozyme, lactoferrin, and lipocalin (3). The presence of lactoferrin, which chelates iron, and lipocalin, which captures the iron-transporting siderophores used by many bacteria, tells us that many microbes would discover the microenvironment of the corneal epithelium to be unfavorably iron-depleted. The corneal epithelium secretes several types of mucin that adhere to the corneal surface (4) and form a barrier that both provides a physical shield from invaders and creates an “unstirred” micron-thick fluid layer between itself and the corneal epithelial cell. Antimicrobial peptides are secreted into this barrier and can accumulate without diffusion (or dilution) into to the tear fluids. Furthermore, we have known for some time that the epithelium expresses several well-characterized antimicrobial peptides, both constitutively and induced following injury (5). These include several of the β-defensins and LL-37 (cathelicidin), which are believed


Acknowledgments

Work in the authors’ laboratory is funded by the Ministerio de Economía y Competitividad, the Innovative Medicines Initiative, the European Commission Seventh Framework Programme, and the Beta Cell Biology Consortium (National Institute of Diabetes and Digestive and Kidney Diseases).

Address correspondence to: Jorge Ferrer, Centre Esther Koplowitz, Villarroel 153, Barcelona, 08036, Spain. Phone: 34.93.227.5400 ext. 4542; Fax: 34.93.451.6638; E-mail: jferrer@clinic.ub.es.
to be secreted from the epithelial cell onto the corneal surface beneath the mucin layer (6). Antimicrobial peptides act by binding to microbial membranes and fatally disturbing their permeability (7). An organism that somehow made it through the mucin layer would then encounter the high concentrations of antimicrobial peptides bathing the surface of corneal epithelial cells, be killed rapidly, and fail to adhere or to penetrate.

Finding a new player
In this issue of JCI, Tam et al. describe another antimicrobial defense of the corneal epithelium that has gone unnoticed to date (8). These investigators hypothesized that there might be additional, as yet undiscovered, antimicrobial peptides being expressed by the human corneal epithelium. To search for these putative peptides, they derived an immortal cell line from human corneal epithelium and differentiated it into mature corneocytes by addition of calcium ions. In vitro, a crude extract of these cultured cells exhibited antibacterial activity against Pseudomonas aeruginosa. Fractionation of the extract on the basis of molecular weight demonstrated that the activity resided in two fractions (less than 3,000 Da and between 3000 and 10,000 Da). Analysis of these fractions by LC/MS identified the principal active molecules to be peptide fragments derived from the carboxy-terminal region of cytokeratin 6A.

To confirm that cytokeratin 6A was the protein from which these peptides originated, Tam et al. demonstrated that reducing cytokeratin 6A expression using siRNA significantly attenuated antibacterial activity (8).

The keratin peptides identified in the extract were synthesized, and their individual activities were studied. Perhaps the most surprising result (for those interested in the details of antimicrobial peptide structure-function) was that several of these short peptides did not exhibit the anticipated sequence and structural characteristics of classical linear antimicrobial peptides, because they were glycine-rich and lacking both a net cationic charge and the tendency to form an α-helix. Several of these peptides exhibited bactericidal activity in vitro against potential ocular pathogens in addition to P. aeruginosa, including S. aureus and Streptococcus pyogenes.

One peptide, a 19-mer with a “classical” cationic amphipathic sequence, was effective in rapidly killing a cytotoxic strain of P. aeruginosa in either water or at physiological ionic conditions (150 mM NaCl), suggesting it would retain activity within the liquid film in contact with the apical surface of the corneal epithelium. This peptide, when introduced into culture medium, effectively protected corneal epithelial cells from invasion and cytotoxicity by P. aeruginosa. Further studies by Tam et al. suggested that this 19-mer bound specifically to the bacterial cytoplasmic membrane and caused it to become leaky, subsequently killing the bacterial cell within minutes of exposure.

Perhaps most remarkably, Tam et al. demonstrated that subconjunctival injection of cytokeratin 6A siRNA into the cornea of a live mouse, reducing expression of cytokeratin 6A by about 25%, resulted in a 5-fold increase in the adherence of P. aeruginosa introduced onto the treated cornea.

The conclusion from these studies is that a cytokeratin, a protein that plays a structural role within cells, appears to protect the surface of the eye. By some mechanism, not as yet understood, fragments of this protein are generated that find their way to the surface of the cornea and kill microbes.

A new role for structural proteins?
Precedents for structural intracellular proteins serving extracellular antimicrobial functions in vertebrates exist. A notable example has been described in the stomach of the Asian toad (9). The 39-amino acid antimicrobial peptide buforin is the N-terminal fragment of histone 2A that appears to play an antimicrobial role on the gastric mucosa of this species. Buforin is produced by the action of gastric pepsin, which acts on unacylated cytoplasmic histone 2A that has been secreted into the gastric lumen (9).

The antimicrobial defense system described by Tam et al. has the capacity to be rapidly mobilized, since it uses an abundant protein already present within the cell. In contrast, the expression of the induced antimicrobial peptides would likely occur over the course of hours. Thus, this system might be critical in the initial phases of microbial assault (Figure 1). Many questions are provoked by this discovery. What mechanisms are involved in the fragmentation of cytokeratin 6A, and what are the proteases involved in the process? Where within the corneal epit-
The explosive growth in our understanding of the molecular underpinnings of glioblastomas has served as an instructive paradigm for other cancers. However, the exact nature by which many of the pathogenic drivers connect is less well known, and elucidation of relationships between critical genetic and signaling alterations may inform the development of therapeudic approaches to the disease. In this issue, Song et al. identify miR-182 induction as a mechanism by which TGF-β stimulation aberrantly activates NF-κB signaling in glioblastoma cells, clarifying a critical point of cross-talk between molecular signaling pathways. Their findings provide a greater understanding of the complex interplay between signaling pathways in cancer that may ultimately prove useful in the development of synergistic targeting approaches.

Glioblastoma (World Health Organization grade IV glioma) is the most prevalent primary brain tumor; these highly lethal cancers are characterized by alterations in multiple critical intracellular signaling networks as well as by inactivation of tumor suppressors (1). Although specific pathways and molecules are frequently hyperactive and appear dominant in glioblastoma, unilateral molecular targeting approaches have been disappointing clinically. For example, most glioblastomas display hyperactive EGFR signaling as a result of increased receptor copy number or oncogenic activating mutations. However, single-agent EGFR targeting has not been successful in clinical trial (2). Because glioblastoma cells display plasticity in signaling networks without addiction to any one oncogene, successful therapy will require multiproonged approaches that impede various active pathways for success with molecularly targeted agents (3). In theory, identification of signaling keystones and their interactions within the structurally complex architecture of glioblastoma will inform the development of effective therapeutic approaches to topple the colossus of cancer signaling.

Mapping the signaling axes

The multiple concerted signaling alterations that contribute to the malignant characteristics of glioblastoma have been interrogated by many researchers. NF-κB pathway activation has emerged as one of the critical central signaling axes in glioblastoma cells. NF-κB signaling can be activated by EGFR signaling, which is often a key feature of gliomas (4). Similarly, the constitutively active EGFRvIII mutant often present in glioblastoma activates NF-κB signaling (5). NF-κB is classically activated by inflammatory-related mechanisms, which also may be present and of oncogenic importance (6). In addition, recent work demonstrates that deletion of NF-κB inhibitor-α (NFKBIA, which encodes IκBα) in glioblastomas with non-amplified EGFR is associated with shorter patient survival, which suggests that NF-κB signaling is a central node in oncogenic signaling both in EGFR-amplified and nonamplified glioma (7). It is worth mentioning that signaling via other activated receptor tyrosine kinases (RTKs) can also stimulate NF-κB signaling. Thus, NF-κB is a central pathway mediating the effects of mitogen-activated signaling pathways like PDGFRA, ERBB2, and MET (1).

Looking in the miR-ror: TGF-β–mediated activation of NF-κB in glioma

Christine E. Eyler1 and Jeremy N. Rich2,3

1Department of Internal Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, USA.
2Department of Stem Cell Biology and Regenerative Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
3Department of Molecular Medicine, Case Western Reserve University School of Medicine and University Hospitals, Cleveland, Ohio, USA.

The multiple concerted signaling alterations that contribute to the malignant characteristics of glioblastoma have been interrogated by many researchers. NF-κB pathway activation has emerged as one of the critical central signaling axes in glioblastoma cells. NF-κB signaling can be activated by EGFR signaling, which is often a key feature of gliomas (4). Similarly, the constitutively active EGFRvIII mutant often present in glioblastoma activates NF-κB signaling (5). NF-κB is classically activated by inflammatory-related mechanisms, which also may be present and of oncogenic importance (6). In addition, recent work demonstrates that deletion of NF-κB inhibitor-α (NFKBIA, which encodes IκBα) in glioblastomas with non-amplified EGFR is associated with shorter patient survival, which suggests that NF-κB signaling is a central node in oncogenic signaling both in EGFR-amplified and nonamplified glioma (7). It is worth mentioning that signaling via other activated receptor tyrosine kinases (RTKs) can also stimulate NF-κB signaling. Thus, NF-κB is a central pathway mediating the effects of mitogen-activated signaling pathways like PDGFRA, ERBB2, and MET (1).